121 related articles for article (PubMed ID: 11996806)
1. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates.
Kotwani RN; Gokhale PC; Bodhe PV; Kirodian BG; Kshirsagar NA; Pandya SK
Int J Pharm; 2002 May; 238(1-2):11-5. PubMed ID: 11996806
[TBL] [Abstract][Full Text] [Related]
2. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
[TBL] [Abstract][Full Text] [Related]
3. Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study.
Kotwani RN; Bodhe PV; Kirodian BG; Mehta KP; Ali US; Kshirsagar NA
Indian Pediatr; 2003 Jun; 40(6):545-50. PubMed ID: 12824664
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics.
Ohata Y; Tomita Y; Suzuki K; Maniwa T; Yano Y; Sunakawa K
Drug Metab Pharmacokinet; 2015 Dec; 30(6):400-9. PubMed ID: 26645511
[TBL] [Abstract][Full Text] [Related]
5. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.
Boswell GW; Bekersky I; Buell D; Hiles R; Walsh TJ
Antimicrob Agents Chemother; 1998 Feb; 42(2):263-8. PubMed ID: 9527770
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients.
Eldem T; Arican-Cellat N; Agabeyoglu I; Akova M; Kansu E
Int J Pharm; 2001 Feb; 213(1-2):153-61. PubMed ID: 11165103
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tolerance of liposomal amphotericin B in patients.
Gokhale PC; Barapatre RJ; Advani SH; Kshirsagar NA; Pandya SK
J Antimicrob Chemother; 1993 Jul; 32(1):133-9. PubMed ID: 8226404
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
9. AmBisome (liposomal amphotericin B): a comparative review.
Boswell GW; Buell D; Bekersky I
J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B in neonates with invasive candidiasis.
al Arishi H; Frayha HH; Kalloghlian A; al Alaiyan S
Am J Perinatol; 1997 Oct; 14(9):573-6. PubMed ID: 9394170
[TBL] [Abstract][Full Text] [Related]
11. Differences in the method by which plasma is separated from whole blood influences amphotericin B plasma recovery and distribution following amphotericin B lipid complex incubation within whole blood.
Ramaswamy M; Wasan KM
Drug Dev Ind Pharm; 2001 Sep; 27(8):871-5. PubMed ID: 11699840
[TBL] [Abstract][Full Text] [Related]
12. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta P; Vinks A; Filipovich A; Vaughn G; Fearing D; Sper C; Davies S
Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B in neonates with invasive candidiasis.
Al Arishi H; Frayha HH; Kalloghlian A; Al Alaiyan S
Am J Perinatol; 1998; 15(11):643-8. PubMed ID: 10064206
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.
Bekersky I; Fielding RM; Dressler DE; Kline S; Buell DN; Walsh TJ
J Clin Pharmacol; 2001 Sep; 41(9):963-71. PubMed ID: 11549101
[TBL] [Abstract][Full Text] [Related]
15. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
Kennedy AL; Wasan KM
J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.
Hope WW; Goodwin J; Felton TW; Ellis M; Stevens DA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5303-8. PubMed ID: 22869566
[TBL] [Abstract][Full Text] [Related]
17. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
18. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis.
Bodhe PV; Kotwani RN; Kirodian BG; Pathare AV; Pandey AK; Thakur CP; Kshirsagar NA
Trans R Soc Trop Med Hyg; 1999; 93(3):314-8. PubMed ID: 10492769
[TBL] [Abstract][Full Text] [Related]
19. Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.
Kwong EH; Ramaswamy M; Bauer EA; Hartsel SC; Wasan KM
Antimicrob Agents Chemother; 2001 Jul; 45(7):2060-3. PubMed ID: 11408223
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
Bingöl B; Bakirel T
J Vet Pharmacol Ther; 2018 Feb; 41(1):e16-e21. PubMed ID: 28815733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
